sarilumab

CHEBI:CHEBI_748893

Drug Classification

Important Medical Information

⚕️ This information is sourced from ChEBI (Chemical Entities of Biological Interest) database and is intended for educational purposes only.

  • Always consult with a healthcare professional before starting, stopping, or modifying any medication.
  • Side effects may vary and this list may not be comprehensive.
  • Drug interactions may occur with other medications.

Additional Identifiers

🔍 Click on any linked disease name to learn more about the conditions this medication is used to treat, or explore related drug classifications for more information about similar medications.

Additional Attributes

rxcui
2003767
generic_name
Sarilumab
product_type
DRUG FOR FURTHER PROCESSING
listing_expiration_date
20241231
dosage_form
INJECTION, SOLUTION
route
SUBCUTANEOUS
marketing_category
DRUG FOR FURTHER PROCESSING
active_ingredient_strength
131.1 mg/mL
labeler_name
sanofi-aventis U.S. LLC
marketing_start_date
20170522
package_marketing_start_date
22-MAY-17
manufacturer_name
sanofi-aventis U.S. LLC
brand_name
KEVZARA
brand_name_base
KEVZARA
product_ndc
0024-5910
application_number
BLA761037
spl_id
77220815-42ec-46e6-b7d1-804a58cad03f
active_ingredient_name
SARILUMAB
package_ndc
0024-5910-02
package_description
2 SYRINGE in 1 PACKAGE (0024-5910-02) / 1.14 mL in 1 SYRINGE
unii
NU90V55F8I
spl_set_id
827bc01c-d379-4266-a18c-c7f904b76af3
nui
N0000190480
pharm_class_epc
Interleukin-6 Receptor Antagonist [EPC]
pharm_class
Interleukin 6 Receptor Antagonists [MoA]
pharm_class_moa
Interleukin 6 Receptor Antagonists [MoA]
22-rdf-syntax-ns#type
http://www.w3.org/2002/07/owl#Class